Calcium Channel Blockers | 1 μM | 3 μM | 10 μM | n |
---|---|---|---|---|
(±)-Tetrandrine | ||||
Cav1.4 | N.S.B. | N.S.B. | N.S.B. | 2 |
Cav1.2 | 236 ± 21 | 277 ± 22 | 290 ± 18 | 3 |
Cav1.3 | 218 ± 9 | 248 ± 12 | 249 ± 9 | 6 |
(+)-cis-Diltiazem | ||||
Cav1.4 | N.S.B. | N.S.B. | N.S.B. | 2 |
Cav1.2 | 116 ± 5 | 134 ± 6 | 171 ± 6 | 4 |
Cav1.3 | 136 ± 3 | 154 ± 5 | 179 ± 6 | 6 |
Mibefradil | ||||
Cav1.4 | N.S.B. | N.S.B. | N.S.B. | 2 |
Cav1.2 | 93 ± 18 | 155 ± 5 | 164 ± 6 | 4 |
Cav1.3 | 42 ± 4 | 63 ± 2 | 71 ± 3 | 6 |
N.S.B., no specific binding was observed in the absence or presence of the indicated concentrations of (±)-tetrandrine, (+)-cis-diltiazem, and mibefradil in membrane preparations of two independent transfections.